panobinostat
Aliases
LBH589
6 clinical trials
1 product
4 abstracts
12 indications
Indication
Sickle Cell DiseaseIndication
GliomaIndication
Diffuse Large B-Cell LymphomaIndication
Colorectal CancerIndication
Primary MyelofibrosisIndication
Polycythemia VeraIndication
Graft-Versus-Host DiseaseIndication
Acute Myeloid LeukemiaIndication
ThalassemiaIndication
Plasma Cell LeukemiaIndication
PlasmacytomaIndication
Multiple MyelomaAbstract
Synergistic cytotoxicity of histone deacetylase, poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: Therapeutic implications.Org: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Clinical trial
Phase I Study to Determine the Safety and Tolerability of Escalating Doses of Panobinostat (LBH589) in Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine GliomaStatus: Completed, Estimated PCD: 2022-02-14
Clinical trial
A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell LymphomaStatus: Completed, Estimated PCD: 2016-01-01
Clinical trial
Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2038-12-31
Clinical trial
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored StudiesStatus: Recruiting, Estimated PCD: 2027-09-16
Clinical trial
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed MyelomaStatus: Completed, Estimated PCD: 2024-06-03
Abstract
MicroOrganoSpheres as a clinically applicable precision oncology platform for the discovery of novel therapies in colorectal cancer.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center,
Abstract
Can epigenetic treatments efficiently revoke the ability of 3D ovarian cancer cells to proliferate, migrate, and invade?Org: Cooper University Hospital, MD Anderson Cancer Center at Cooper,
Abstract
Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.Org: RTI Health Solutions, Pfizer Inc., London, United Kingdom,
Product
panobinostat + bevacizumab